

Apple Health PDL Drug Class Motions

Antipsychotic Agents

- ▶ 1st Generation
- ▶ 2nd Generation
- ▶ Combinations
- ▶ Miscellaneous

Antipsychotic Agents

▶ Recommendation:

- ▶ All products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of three preferred products, one of which must be a preferred generic, before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antipsychotic Agents

- ▶ **Motion:** I move that all products in the Antipsychotic - drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of three preferred products within the same sub-class, one of which must be a preferred generic, before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion: Buccola**

▶ **2nd: Park**

Antimanic Agents

▶ Recommendation:

- ▶ All products in the Antimanic Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antimanic Agents

- ▶ **Motion:** I move that all products in the Antimanic Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Park**
- ▶ **2nd: Storhaug**

Migraine Agents- Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists

► Recommendation:

- ▶ All products in the Migraine Agents- CGRP Receptor Antagonists are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All CGRP Receptor Antagonists require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Migraine Agents- Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists

► **Motion:** I move that all products in the Migraine Agents- CGRP drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All drugs within this class may require prior authorization for medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

► **Motion: Schwilke**

► **2nd: Flatebo**

Migraine Agents- 5HT1 Agonists (Triptans)

▶ Recommendation:

- ▶ All products in the Migraine Agents- 5HT1 Agonists are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Migraine Agents

- ▶ Ergot Derivatives

- ▶ Other

- ▶ Triptans

- ▶ **Recommendation:**

- ▶ All products in the Migraine Agents – Ergot Derivatives and Migraine Agents - Other drug classes are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Migraine Agents

- ▶ Ergot Derivatives
- ▶ Other
- ▶ Triptans

- ▶ **Motion:** All products in the Migraine Agents classes are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products in their respective class before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Storhaug**
- ▶ **2nd: Park**

Antihypertensives

- ▶ ACE Inhibitors/Combinations
- ▶ Angiotensin II Receptor Blockers/Combinations
- ▶ Neprilysin Inhibitor (ARNI)- Angiotensin II Receptor Antagonist Combinations
- ▶ Direct Renin Inhibitors/Combinations
- ▶ Beta-Blockers/Combinations
- ▶ Calcium Channel Blockers/Combinations
- ▶ Diuretics

Antihypertensives

► Recommendation:

- ▶ All products in the drug classes listed on slide 12 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Neprilysin Inhibitor (ARNI)- Angiotensin II Receptor Antagonist Combinations require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication within their respective class before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred

Antihypertensives

- ▶ **Motion:** I move that all products in the Antihypertensive drug classes listed on slide 12 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Neprilysin Inhibitor (ARNI)- Angiotensin II Receptor Antagonist Combinations may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication within their respective class before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2nd: Schwilke**

Cardiovascular Agents - Nitrates

▶ Recommendation:

- ▶ All products in the Cardiovascular Agents- Nitrates drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Cardiovascular Agents- Nitrates

► **Motion:** I move that all products in the Cardiovascular Agents- Nitrates drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

► **Motion: Brown**

► **2nd: Park**

Cardiovascular Agents – Sinus Node Inhibitors

▶ Recommendation:

- ▶ All products in the Cardiovascular Agents- Sinus Node Inhibitors drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Cardiovascular Agents – Sinus Node Inhibitors

- ▶ **Motion:** I move that all products in the Cardiovascular Agents- Sinus Node Inhibitors drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Sinus node inhibitors may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2nd: Schwilke**

Cardiovascular Agents – Pulmonary Hypertension

- ▶ Endothelin Receptor Antagonists
- ▶ PDEI
- ▶ Prostacyclin Receptor Agonists
- ▶ SGC Stimulator
- ▶ Prostaglandin Vasodilators

Cardiovascular Agents – Pulmonary Hypertension

► Recommendation:

- ▶ All products in the drug classes listed on slide 19 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Pulmonary hypertension agents may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred

Cardiovascular Agents – Pulmonary Hypertension

- ▶ **Motion:** I move that all products in the drug classes listed on slide 19 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Pulmonary hypertension agents may require prior authorization to determine medical necessity.
- ▶ **Motion: Park**
- ▶ **2nd: Flatebo**

Bone Density Regulators

- ▶ Bisphosphonates
- ▶ Calcitonins
- ▶ Parathyroid Hormone Derivatives
- ▶ Rank Ligand Inhibitors
- ▶ Sclerostin Inhibitors
- ▶ Selective Estrogen Receptor Modulators (SERMS)

Bone Density Regulators

▶ Recommendation:

- ▶ All products in the drug classes listed on slide 22 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Bone density regulators may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred

Bone Density Regulators

- ▶ **Motion:** I move that all products in the drug classes listed on slide 22 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Bone density regulators may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication within their respective drug class, before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2nd: Park**

Antiemetics/Antivertigo Agents - 5-HT3 Receptor Antagonists

► Recommendation:

- ▶ All products in the Antiemetics/Antivertigo Agents- 5-HT3 Receptor Antagonists drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antiemetics/Antivertigo Agents - 5-HT3 Receptor Antagonists

- ▶ **Motion:** I move that all products in the Antiemetics/Antivertigo Agents- 5-HT3 Receptor Antagonists drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2nd: Lee**

Antiemetics/Antivertigo Agents

- ▶ Substance P/Neurokinin 1 (NK1) Receptor Antagonists/Combinations
- ▶ Other
- ▶ **Recommendation:**
 - ▶ All products in the drug classes listed above are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
 - ▶ Antiemetics/Antivertigo agents may require prior authorization to determine medical necessity.
 - ▶ All non-preferred products require a trial of two preferred products before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred

Antiemetics/Antivertigo Agents

- ▶ Substance P/Neurokinin 1 (NK1) Receptor Antagonists
- ▶ Other
- ▶ **Motion:** I move that all products in the drug classes listed on slide 27 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Antiemetics/Antivertigo agents may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products in their respective drug class before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Schwilke**
- ▶ **2nd: Brown**

Substance Use Disorder

- ▶ Opioid Antagonists
- ▶ Opioid Partial Agonists
- ▶ Substance use disorder- other

- ▶ **Recommendation:**

- ▶ All products in the drug classes listed above are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred

Substance Use Disorder

- ▶ Opioid Antagonists
- ▶ Opioid Partial Agonists
- ▶ Substance use disorder- other

- ▶ **Motion:** I move that all products in the drug classes listed on slide 29 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products within their respective drug class before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Park**
- ▶ **2nd: Buccola**

Prostatic Hypertrophy Agents

▶ Recommendation:

- ▶ All products in the Prostatic Hypertrophy Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Prostatic Hypertrophy Agents

► **Motion:** I move that all products in the Prostatic Hypertrophy Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

► **Motion: Buccola**

► **2nd: Schwilke**

Androgens - Testosterone

▶ Recommendation:

- ▶ All products in the Androgens- Testosterone drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Testosterone products may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Androgens - Testosterone

► **Motion:** I move that all products in the Androgens- Testosterone drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Testosterone products may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

► **Motion: Lee**

► **2nd: Park**